Trial Outcomes & Findings for A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp (NCT NCT00669214)

Last Updated: 2017-06-06

Results Overview

Proportion of patients who achieved a ≥ 75% decrease in PSSI score at 12 weeks (Day 84) relative to baseline. The PSSI assessed: 1) extent of scalp psoriasis (i.e., percentage of area involved), which was scored from 1 to 6, where 1 = \<10% and 6 = 90-100%); and 2) clinical signs (erythema, induration, and desquamation), which were scored from 0 to 4, where 0 = Absent and 4 = Severest possible). The sum of the separate scores for erythema, induration, and desquamation was multiplied by the score for the involved area. The PSSI score range was therefore 0-72.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

89 participants

Primary outcome timeframe

Week 12

Results posted on

2017-06-06

Participant Flow

Participant milestones

Participant milestones
Measure	Placebo All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Double-Blind Treatment Period (Week 12) STARTED	27	62
Double-Blind Treatment Period (Week 12) COMPLETED	22	55
Double-Blind Treatment Period (Week 12) NOT COMPLETED	5	7
Open-Label Treatment Period (Week 24) STARTED	22	55
Open-Label Treatment Period (Week 24) COMPLETED	18	46
Open-Label Treatment Period (Week 24) NOT COMPLETED	4	9

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=27 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=62 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Total n=89 Participants Total of all reporting groups
Age, Continuous	42.78 years STANDARD_DEVIATION 16.53 • n=5 Participants	43.16 years STANDARD_DEVIATION 13.46 • n=7 Participants	43.04 years STANDARD_DEVIATION 14.37 • n=5 Participants
Sex: Female, Male Female	9 Participants n=5 Participants	30 Participants n=7 Participants	39 Participants n=5 Participants
Sex: Female, Male Male	18 Participants n=5 Participants	32 Participants n=7 Participants	50 Participants n=5 Participants

PRIMARY outcome

Timeframe: Week 12

Population: Intent-to-treat (ITT) population. If PSSI at Day 84 was missing for a patient who discontinued before the final scheduled dose, the patient was considered a treatment failure (nonresponder) for analysis. If PSSI at Day 84 was missing for a patient who completed treatment, the last available PSSI from the treatment period was used for analysis.

Outcome measures

Outcome measures
Measure	Placebo n=27 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=62 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Proportion of Patients Who Achieved a ≥ 75% Decrease in Psoriasis Scalp Severity Index (PSSI) Score at 12 Weeks	0.111 Proportion of patients	0.274 Proportion of patients

SECONDARY outcome

Timeframe: Week 24

Population: ITT population. If PSSI at Day 168 was missing for a patient who discontinued before the final scheduled open-label dose, the patient was considered a treatment failure (nonresponder) for analysis. If PSSI at Day 168 was missing for a patient who completed the Day 161 dose, the last available PSSI was used for analysis.

Proportion of patients who achieved a ≥ 75% decrease in PSSI score at 24 weeks (Day 168) relative to baseline. The PSSI assessed: 1) extent of scalp psoriasis (i.e., percentage of area involved), which was scored from 1 to 6, where 1 = \<10% and 6 = 90-100%); and 2) clinical signs (erythema, induration, and desquamation), which were scored from 0 to 4, where 0 = Absent and 4 = Severest possible). The sum of the separate scores for erythema, induration, and desquamation was multiplied by the score for the involved area. The PSSI score range was therefore 0-72.

Outcome measures

Outcome measures
Measure	Placebo n=22 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=62 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Proportion of Patients Who Achieved a ≥ 75% Decrease in PSSI Score at 24 Weeks	0.273 Proportion of patients Interval 0.107 to 0.502	0.323 Proportion of patients Interval 0.209 to 0.453

SECONDARY outcome

Timeframe: Week 12

Population: ITT population. If PSSI at Day 84 was missing for a patient who discontinued before the final scheduled dose, the patient was considered a treatment failure (nonresponder) for analysis. If PSSI at Day 84 was missing for a patient who completed treatment, the last available PSSI from the treatment period was used for analysis.

Proportion of patients who achieved a ≥ 50% decrease in PSSI score at 12 weeks (Day 84) relative to baseline. The PSSI assessed: 1) extent of scalp psoriasis (i.e., percentage of area involved), which was scored from 1 to 6, where 1 = \<10% and 6 = 90-100%); and 2) clinical signs (erythema, induration, and desquamation), which were scored from 0 to 4, where 0 = Absent and 4 = Severest possible). The sum of the separate scores for erythema, induration, and desquamation was multiplied by the score for the involved area. The PSSI score range was therefore 0-72.

Outcome measures

Outcome measures
Measure	Placebo n=27 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=62 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Proportion of Patients Who Achieved a ≥ 50% Decrease in PSSI Score at 12 Weeks	0.296 Proportion of patients	0.452 Proportion of patients

SECONDARY outcome

Timeframe: Week 24

Proportion of patients who achieved a ≥ 50% decrease in PSSI score at 24 weeks (Day 168) relative to baseline. The PSSI assessed: 1) extent of scalp psoriasis (i.e., percentage of area involved), which was scored from 1 to 6, where 1 = \<10% and 6 = 90-100%); and 2) clinical signs (erythema, induration, and desquamation), which were scored from 0 to 4, where 0 = Absent and 4 = Severest possible). The sum of the separate scores for erythema, induration, and desquamation was multiplied by the score for the involved area. The PSSI score range was therefore 0-72.

Outcome measures

Outcome measures
Measure	Placebo n=22 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=62 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Proportion of Patients Who Achieved a ≥ 50% Decrease in PSSI Score at 24 Weeks	0.455 Proportion of patients Interval 0.244 to 0.678	0.500 Proportion of patients Interval 0.37 to 0.63

SECONDARY outcome

Timeframe: Week 12

Population: ITT population. If PGA rating at Day 84 was missing for a patient who discontinued before the final scheduled dose, the patient was considered a treatment failure (nonresponder) for analysis. If PGA rating at Day 84 was missing for a patient who completed treatment, the last available PGA rating from the treatment period was used for analysis.

Proportion of patients who achieved a whole body (including scalp) PGA rating of 0, 1, or 2 at 12 weeks (Day 84) Physician's Global Assessment (PGA) scale: 0: Clear. No signs of plaque psoriasis. 1. Almost clear. Just perceptible erythema and just perceptible scaling. 2. Mild disease. Light pink erythema with minimal scaling. 3. Moderate disease. Dull red, clearly distinguishable erythema with diffuse scaling, some thickening. 4. Severe disease. Deep/dark red erythema with clearly obvious and diffuse scaling and thickening.

Outcome measures

Outcome measures
Measure	Placebo n=27 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=62 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Proportion of Patients Who Achieved a Whole Body (Including Scalp) Physician's Global Assessment (PGA) Rating of Clear (0), Almost Clear (1), or Mild (2) at 12 Weeks	0.111 Proportion of patients	0.339 Proportion of patients

SECONDARY outcome

Timeframe: Week 24

Population: ITT population. If PGA rating at Day 168 was missing for a patient who discontinued before the final scheduled open-label dose, the patient was considered a treatment failure (nonresponder) for analysis. If PGA rating at Day 168 was missing for a patient who completed the Day 161 dose, the last available PGA rating was used for analysis.

Proportion of patients who achieved a whole body (including scalp) PGA rating of 0, 1, or 2 at 24 weeks (Day 168) For details on the PGA scale, refer to the Secondary Outcome Measure Description for 12 weeks.

Outcome measures

Outcome measures
Measure	Placebo n=22 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=62 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Proportion of Patients Who Achieved a Whole Body (Including Scalp) PGA Rating of Clear (0), Almost Clear (1), or Mild (2) at 24 Weeks	0.545 Proportion of patients Interval 0.322 to 0.756	0.387 Proportion of patients Interval 0.266 to 0.519

SECONDARY outcome

Timeframe: The two time points for Mean Change in Scalpdex Score at 12 Weeks are Day 0 and Day 84

Population: ITT population. If Scalpdex at Day 84 was missing for a patient who discontinued before the final scheduled dose, the patient was not included in the analysis. If Scalpdex at Day 84 was missing for a patient who completed treatment, the last available Scalpdex from the treatment period was used for analysis.

Mean change in Scalpdex score at 12 weeks (Day 84) relative to baseline. The Scalpdex point scoring scale ranges from 1=NEVER, 2='RARELY', 3='SOMETIMES', 4='OFTEN' and 5='ALL THE TIME'.

Outcome measures

Outcome measures
Measure	Placebo n=22 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=55 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Mean Change in Scalpdex Score at 12 Weeks Baseline Score	63.91 Points on Scalpdex Standard Deviation 15.40	67.83 Points on Scalpdex Standard Deviation 13.88
Mean Change in Scalpdex Score at 12 Weeks Week 12 Change from Baseline	6.82 Points on Scalpdex Standard Deviation 7.76	10.15 Points on Scalpdex Standard Deviation 13.56

SECONDARY outcome

Timeframe: Week 24

Population: ITT population. If Scalpdex at Day 168 was missing for a patient who discontinued before the final scheduled dose, the patient was not included in the analysis. If Scalpdex at Day 168 was missing for a patient who completed the Day 161 dose, the last available Scalpdex was used for analysis.

Mean change in Scalpdex score at 24 weeks (Day 168) relative to baseline. The Scalpdex point scoring scale ranges from 1=NEVER, 2='RARELY', 3='SOMETIMES', 4='OFTEN' and 5='ALL THE TIME'.

Outcome measures

Outcome measures
Measure	Placebo n=18 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=47 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Mean Change in Scalpdex Score at 24 Weeks Baseline Score	63.91 Points on Scalpdex Standard Deviation 15.40	67.83 Points on Scalpdex Standard Deviation 13.88
Mean Change in Scalpdex Score at 24 Weeks Week 24 Change from Baseline	7.81 Points on Scalpdex Standard Deviation 9.80	13.26 Points on Scalpdex Standard Deviation 14.02

SECONDARY outcome

Timeframe: Week 12

Population: ITT population. If VAS at Day 84 was missing for a patient who discontinued before the final scheduled dose, the patient was not included in the analysis. If VAS at Day 84 was missing for a patient who completed treatment, the last available VAS from the treatment period was used for analysis.

Mean change in VAS of patient-reported scalp itch at 12 weeks (Day 84) relative to baseline. The Visual Analog Scale (VAS) of patient-reported scalp itch measured the severity of a patient's scalp itch on a scale of 0 to 10, where 0 was "no itching," 5 was "moderate itching," and 10 was "severe itching."

Outcome measures

Outcome measures
Measure	Placebo n=22 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=54 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Mean Change in a Visual Analog Scale (VAS) of Scalp Itch at 12 Weeks Baseline Scale	6.81 Points on VAS Standard Deviation 2.34	7.47 Points on VAS Standard Deviation 2.24
Mean Change in a Visual Analog Scale (VAS) of Scalp Itch at 12 Weeks Week 12 Change from Baseline	1.00 Points on VAS Standard Deviation 1.95	2.19 Points on VAS Standard Deviation 2.91

SECONDARY outcome

Timeframe: Week 24

Population: ITT population. If VAS at Day 168 was missing for a patient who discontinued before the final scheduled dose, the patient was not included in the analysis. If VAS at Day 168 was missing for a patient who completed the Day 161 dose, the last available VAS was used for analysis.

Mean change in VAS of patient-reported scalp itch at 24 weeks (Day 168) relative to baseline. The Visual Analog Scale (VAS) of patient-reported scalp itch measured the severity of a patient's scalp itch on a scale of 0 to 10, where 0 was "no itching," 5 was "moderate itching," and 10 was "severe itching."

Outcome measures

Outcome measures
Measure	Placebo n=18 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=46 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Mean Change in VAS of Patient-reported Scalp Itch at 24 Weeks Baseline Points	6.81 Points on VAS Standard Deviation 2.34	7.47 Points on VAS Standard Deviation 2.24
Mean Change in VAS of Patient-reported Scalp Itch at 24 Weeks Week 24 Change from Baseline	2.06 Points on VAS Standard Deviation 3.61	3.07 Points on VAS Standard Deviation 3.09

SECONDARY outcome

Timeframe: Week 12

Population: ITT population. N's reflect patients who received at least one dose of study drug or placebo in the double-blind treatment period.

Mean change in percentage of whole body (including scalp) BSA affected by psoriasis at 12 weeks (Day 84) relative to baseline. BSA was assessed by percentage of sites affected per body segment (head, trunk, and limbs). Investigators were instructed to use the "rule of palm" to estimate lesional skin BSA (1% BSA = palm to first interphalangeal joint).

Outcome measures

Outcome measures
Measure	Placebo n=22 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=56 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Mean Change in Percentage of Whole Body (Including Scalp) Body Surface Area (BSA) Affected by Psoriasis at 12 Weeks Baseline BSA	14.74 Pecentage of BSA Standard Deviation 15.48	19.61 Pecentage of BSA Standard Deviation 18.51
Mean Change in Percentage of Whole Body (Including Scalp) Body Surface Area (BSA) Affected by Psoriasis at 12 Weeks Week 12 Change from Baseline	2.00 Pecentage of BSA Standard Deviation 5.65	6.43 Pecentage of BSA Standard Deviation 10.30

SECONDARY outcome

Timeframe: Week 24

Population: ITT population. N's reflect patients who received at least one dose of study drug in the open-label period.

Mean change in percentage of whole body (including scalp) BSA affected by psoriasis at 24 weeks (Day 168) relative to baseline. BSA was assessed by percentage of sites affected per body segment (head, trunk, and limbs). Investigators were instructed to use the "rule of palm" to estimate lesional skin BSA (1% BSA = palm to first interphalangeal joint).

Outcome measures

Outcome measures
Measure	Placebo n=18 Participants All patients received a conditioning dose of placebo equivalent subcutaneously (SC) on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab n=48 Participants All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Mean Change in Percentage of Whole Body (Including Scalp) BSA Affected by Psoriasis at 24 Weeks Baseline BSA	14.74 Percentage of BSA Standard Deviation 15.48	19.61 Percentage of BSA Standard Deviation 18.51
Mean Change in Percentage of Whole Body (Including Scalp) BSA Affected by Psoriasis at 24 Weeks Week 24 Change from Baseline	4.53 Percentage of BSA Standard Deviation 6.53	7.53 Percentage of BSA Standard Deviation 12.59

Adverse Events

Placebo: Double-Blind Period

Serious events: 1 serious events

Other events: 11 other events

Deaths: 0 deaths

Efalizumab: Double-Blind Period

Serious events: 1 serious events

Other events: 32 other events

Deaths: 0 deaths

Placebo: Open-Label Period

Serious events: 0 serious events

Other events: 11 other events

Deaths: 0 deaths

Efalizumab: Open-Label Period

Serious events: 1 serious events

Other events: 22 other events

Deaths: 0 deaths

Placebo: Follow-Up Period

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Efalizumab: Follow-Up Period

Serious events: 2 serious events

Other events: 15 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo: Double-Blind Period n=27 participants at risk All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab: Double-Blind Period n=55 participants at risk；n=62 participants at risk All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Placebo: Open-Label Period n=22 participants at risk	Efalizumab: Open-Label Period n=55 participants at risk	Placebo: Follow-Up Period n=18 participants at risk	Efalizumab: Follow-Up Period n=48 participants at risk
Cardiac disorders Atrial fibrillation	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/62 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Gastrointestinal disorders Abdominal pain	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/62 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Injury, poisoning and procedural complications Injury	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/62 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/62 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Renal and urinary disorders Nephrolithiasis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.6% 1/62 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48

Other adverse events

Other adverse events
Measure	Placebo: Double-Blind Period n=27 participants at risk All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Efalizumab: Double-Blind Period n=55 participants at risk；n=62 participants at risk All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).	Placebo: Open-Label Period n=22 participants at risk	Efalizumab: Open-Label Period n=55 participants at risk	Placebo: Follow-Up Period n=18 participants at risk	Efalizumab: Follow-Up Period n=48 participants at risk
Gastrointestinal disorders Hypoaesthesia oral	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Blood and lymphatic system disorders Splenomegaly	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Ear and labyrinth disorders Ear discomfort	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Ear and labyrinth disorders Vertigo	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Eye disorders Conjunctivitis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Gastrointestinal disorders Dental caries	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Gastrointestinal disorders Diarrhea	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Gastrointestinal disorders Dyspepsia	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Gastrointestinal disorders Abdominal pain upper	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Gastrointestinal disorders Nausea	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Gastrointestinal disorders Vomiting	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
General disorders Fatigue	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
General disorders Malaise	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
General disorders Feeling hot	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
General disorders Influenza like illness	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	3.6% 2/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
General disorders Injection site hematoma	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
General disorders Cyst rupture	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
General disorders Pain	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Immune system disorders Seasonal allergy	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Conjunctivitis bacterial	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Folliculitis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Gastroenteritis bacterial	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Cat scratch disease	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Ear infection	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Fungal infection	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Herpes zoster	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	5.6% 1/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Oral herpes	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Localised infection	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Influenza	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Bronchitis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	3.6% 2/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	5.6% 1/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Pneumonia	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Bacteremia	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Impetigo	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Tinea infection	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Nasopharyngitis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	3.6% 2/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	6.2% 3/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Sinusitis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	5.6% 1/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Upper respiratory tract infection	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	5.5% 3/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Urinary tract infection	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	3.6% 2/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Injury, poisoning and procedural complications Joint sprain	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Injury, poisoning and procedural complications Muscle strain	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Injury, poisoning and procedural complications Excoriation	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Injury, poisoning and procedural complications Wound	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Injury, poisoning and procedural complications Sunburn	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	7.3% 4/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Injury, poisoning and procedural complications Back injury	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Investigations Full blood count abnormal	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Investigations Blood glucose increased	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	5.6% 1/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Investigations Colonoscopy	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Investigations Alanine aminotransferase increased	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Investigations Aspartate aminotransferase increased	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Investigations Blood potassium decreased	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Metabolism and nutrition disorders Anorexia	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Metabolism and nutrition disorders Hypercholesterolemia	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Arthritis	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Polyarthritis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Arthralgia	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	3.6% 2/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	3.6% 2/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.2% 2/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Muscular weakness	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Back pain	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Musculoskeletal pain	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	9.1% 2/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Musculoskeletal and connective tissue disorders Psoriatic arthropathy	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Nervous system disorders Headache	7.4% 2/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	18.2% 10/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	13.6% 3/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	5.6% 1/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Nervous system disorders Sinus headache	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Nervous system disorders Dizziness	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Reproductive system and breast disorders Menorrhagia	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Respiratory, thoracic and mediastinal disorders Diaphragmatic hernia	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Respiratory, thoracic and mediastinal disorders Respiratory tract congestion	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	3.6% 2/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	5.6% 1/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Skin and subcutaneous tissue disorders Acne	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Skin and subcutaneous tissue disorders Dermatitis contact	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Skin and subcutaneous tissue disorders Photosensitivity reaction	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Skin and subcutaneous tissue disorders Pruritus	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	2.1% 1/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Skin and subcutaneous tissue disorders Guttate psoriasis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Skin and subcutaneous tissue disorders Psoriasis	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	9.1% 5/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	9.1% 2/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	5.5% 3/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.2% 2/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Skin and subcutaneous tissue disorders Rosacea	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Vascular disorders Hypertension	3.7% 1/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	4.5% 1/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48
Infections and infestations Nephrolithiasis	0.00% 0/27 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	1.8% 1/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/22 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/55 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/18 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48	0.00% 0/48 • Double-blind (12 weeks), open-label (24 weeks), and follow-up. Patients entered each period as follows: Double-blind: placebo n = 27; efalizumab n = 62 Open-label: placebo n = 22; efalizumab n = 55 Follow-up: placebo n = 18; efalizumab n = 48

Additional Information

Medical Communications

Genentech, Inc.

Phone: 800-821-8590

Results disclosure agreements

Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER